Relationship between bleeding episodes, health-related quality of life and direct costs in adults with severe haemophilia A: Secondary analyses from the CHESS study

Authors: O’Hara, J; Noone, D; Watt, M

Affiliations: HCD Economics, Daresbury, Cheshire, UK. Department of Health and Social Care, University of Chester, Chester, UK. HCD Economics, Daresbury, Cheshire, UK. Takeda Pharmaceuticals International AG, Zurich, Switzerland.

Publication: Haemophilia; 2022

Abstract: To the Editors, The prevalence of significant morbidities and the high cost of care associated with severe haemophilia A contribute to both impaired health-related quality of life (HRQoL) for patients and significant financial impact on healthcare budgets.1–3 Findings from CHESS (Cost of Haemophilia across Europe—a Socioeconomic Survey), a questionnaire-based cost-of-illness survey in patients with haemophilia A and B in five European countries (France, Germany, Italy, Spain and the United Kingdom), revealed the total annual cost of severe haemophilia in 2014 was €1.55 billion (just under €200,000 per patient), driven by consumption of clotting factor replacement therapy.4 Estimated total indirect costs, driven by patient and care-giver work loss, were €43.3 million (€6075 per patient). However, the relationship between the number of bleeding episodes experienced by patients and their HRQoL as well as the impact on direct costs were not explored in depth. In this secondary analysis, we evaluated data from CHESS to increase our understanding of the impact of bleeding on HRQoL and on drug-related and non-drug-related direct costs among adults with severe haemophilia A without inhibitors.